Please login to the form below

Not currently logged in
Email:
Password:

Shire's Replagal is fast-tracked by the FDA

Shire has received Fast Track designation from the FDA for its enzyme replacement therapy for Fabry disease, Replagal (agalsidase alfa)

Speciality biopharmaceutical company, Shire has received Fast Track designation from the FDA for its enzyme replacement therapy for Fabry disease, Replagal (agalsidase alfa).

Shire requested Fast Track designation at the suggestion of the FDA after the regulator requested additional data to back-up Shire's Biologics License Application (BLA), which the pharma company then withdrew.

Following its receipt of Fast Track approval, Shire will initiate the rolling submission of the Replagal BLA, and will submit the requested additional data later this year.

"We will continue to work closely with the FDA in the coming months on the rolling BLA submission for Replagal," said Sylvie Grégoire, president, Shire Human Genetic Therapies. "We remain committed to continuing to provide Fabry patients in the United States with Replagal under the treatment protocol."

Replagal is currently approved for the treatment of Fabry disease in 45 countries worldwide. The drug was made available to US patients in December 2009 through the Replagal early access programme, an FDA-approved treatment protocol, put in place as a result of the supply disruption of the only currently marketed treatment for Fabry disease in the US.

Fabry disease is estimated to affect between 8,000 and 10,000 people worldwide. The condition affects both men and women and can reduce lifespan by around 20 years in men and 15 years in women. Principal causes of death are renal failure, cardiomyopathy and cerebrovascular events such as stroke.

25th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics